Biochemistry Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
PLoS One. 2012;7(5):e37874. doi: 10.1371/journal.pone.0037874. Epub 2012 May 30.
Selection of amino acid substitutions associated with resistance to nucleos(t)ide-analog (NA) therapy in the hepatitis B virus (HBV) reverse transcriptase (RT) and their combination in a single viral genome complicates treatment of chronic HBV infection and may affect the overlapping surface coding region. In this study, the variability of an overlapping polymerase-surface region, critical for NA resistance, is investigated before treatment and under antiviral therapy, with assessment of NA-resistant amino acid changes simultaneously occurring in the same genome (linkage analysis) and their influence on the surface coding region.
METHODOLOGY/PRINCIPAL FINDINGS: Serum samples obtained from chronic HBV-infected patients at pre-treatment and during sequential NA treatment with lamivudine, adefovir, and entecavir were analyzed by ultra-deep pyrosequencing (UDPS) using the GS-FLX platform (454 Life Sciences-Roche). The pre-treatment HBV quasispecies was not enriched with NA-resistant substitutions. The frequencies of this type of substitutions at pre-treatment did not predict the frequencies observed during lamivudine treatment. On linkage analysis of the RT region studied, NA-resistant HBV variants (except for rtA181T) were present in combinations of amino acid substitutions that increased in complexity after viral breakthrough to entecavir, at which time the combined variant rtL180M-S202G-M204V-V207I predominated. In the overlapping surface region, NA-resistant substitutions caused selection of stop codons in a significant percentage of sequences both at pre-treatment and during sequential treatment; the rtA181T substitution, related to sW172stop, predominated during treatment with lamivudine and adefovir. A highly conserved RT residue (rtL155), even more conserved than the essential residues in the RT catalytic motif YMDD, was identified in all samples.
UDPS methodology enabled quantification of HBV quasispecies variants, even those harboring complex combinations of amino acid changes. The high percentage of potentially defective genomes, especially in the surface region, suggests effective trans-complementation of these variants.
乙型肝炎病毒 (HBV) 逆转录酶 (RT) 中与核苷(酸)类似物 (NA) 治疗耐药相关的氨基酸取代的选择及其在单个病毒基因组中的组合使慢性 HBV 感染的治疗复杂化,并可能影响重叠的表面编码区。在这项研究中,在治疗前和抗病毒治疗期间,研究了对 NA 耐药至关重要的重叠聚合酶-表面区域的变异性,同时评估了同一基因组中同时发生的 NA 耐药氨基酸变化(连锁分析)及其对表面编码区的影响。
方法/主要发现:使用 GS-FLX 平台 (454 Life Sciences-Roche) 的超深度焦磷酸测序 (UDPS) 分析了来自慢性 HBV 感染患者的血清样本,这些患者在接受拉米夫定、阿德福韦酯和恩替卡韦的序贯 NA 治疗时进行了分析。治疗前 HBV 准种未富集 NA 耐药取代。治疗前这种类型取代的频率并不能预测拉米夫定治疗期间观察到的频率。在研究的 RT 区域的连锁分析中,NA 耐药的 HBV 变体(除了 rtA181T)存在于氨基酸取代的组合中,这些组合在病毒突破到恩替卡韦时变得更加复杂,此时主要是组合变体 rtL180M-S202G-M204V-V207I。在重叠的表面区域中,NA 耐药取代导致在治疗前和序贯治疗期间,在很大比例的序列中选择了终止密码子;在拉米夫定和阿德福韦酯治疗期间,与 sW172stop 相关的 rtA181T 取代占主导地位。在所有样本中都鉴定出一个高度保守的 RT 残基(rtL155),它比 RT 催化基序 YMDD 中的必需残基更保守。
UDPS 方法能够定量检测 HBV 准种变体,即使是那些含有复杂氨基酸变化组合的变体。高比例的潜在缺陷基因组,尤其是在表面区域,表明这些变体的有效跨互补。